retatrutide telehealth Peptide Therapy Retatrutide Phase 3: 60% Achieved

Heres what you need to know about GLP-1 Agonists

March 2018

Be mindful of portion sizes and dont self-medicate with alcohol during emotional transitions

On 21 May 2026 , Lilly published the long-awaited topline results from the TRIUMPH-1 Phase 3 trial, and the data is striking: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks , with 45.3% of patients losing 30% or more a threshold previously only achievable with bariatric surgery

All the aforementioned results have suggested that GLP-1RAs are safe and beneficial for the treatment of pancreatitis and pancreatic cancer

It must also be marketed with structure-function claims rather than disease or drug claims